Download PDF
Thromb Haemost 2012; 108(02): 394-396
DOI: 10.1160/TH12-03-0201
Letters to the Editor
Schattauer GmbH

The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome

Theodore E. Warkentin
1   Department of Pathology and Molecular Medicine, and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Anup K. Chakraborty
2   Pulmonary Specialties, LLC, Lincoln, Nebraska, USA
,
Jo-Ann I. Sheppard
1   Department of Pathology and Molecular Medicine, and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Danielle K. Griffin
2   Pulmonary Specialties, LLC, Lincoln, Nebraska, USA
› Author Affiliations Financial support: This study was supported by the Heart and Stroke Foundation of Ontario (operating grant #T6950 [T.E. Warken-tin]).
Further Information

Publication History

Received: 28 March 2012

Accepted after minor revision: 25 April 2012

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost 2011; 106: 993-994.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 07 (Suppl. 01) 9-12.
    CrossrefPubMedGoogle Scholar
  • 3 Warkentin TE, Maurer BT, Aster RH. Heparin-in-duced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2654.
    CrossrefPubMedGoogle Scholar
  • 4 Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-781.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Salem M, Elrefai S, Shrit MA. et al. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost 2010; 104: 1071-1072.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc Bayl Univ Med Cent 2012; 25: 13-15.
    PubMedGoogle Scholar
  • 7 Warkentin TE, Cook RJ, Marder VJ. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
    CrossrefPubMedGoogle Scholar
  • 8 Savi P, Chong BH, Greinacher A. et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139-144.
    CrossrefPubMedGoogle Scholar
  • 9 Warkentin TE, Davidson BL, Büller HR. et al. Prevalence and risk of preexisting heparininduced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140: 366-373.
    CrossrefPubMedGoogle Scholar
  • 10 Greinacher A. Immunogenic but effective: the HIT-fondaparinux brain puzzler. J Thromb Haemost 2011; 09: 2386-2388.
    CrossrefPubMedGoogle Scholar
  • 11 Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
    CrossrefPubMedGoogle Scholar
  • 12 Warkentin TE, Linkins LA. Non-necrotizing hepa-rin-induced skin lesions and the 4T’s score. J Thromb Haemost 2010; 08: 1483-1485.
    CrossrefPubMedGoogle Scholar
  • 13 Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real world issues. Semin Thromb Hemost 2011; 37: 653-663.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Warkentin TE. Fondaparinux: does it cause HIT? can it treat HIT?. Expert Rev Hematol 2010; 03: 567-581.
    CrossrefPubMedGoogle Scholar